The Global Medicinal Radiocompounds Market was valued at USD 7.82 Billion in 2024 and is projected to reach USD 13.15 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 8.9% during the forecast period (2024–2030). This robust growth is driven by the increasing prevalence of cancer and cardiovascular diseases, the expanding applications of nuclear medicine in diagnostics and therapeutics (theranostics), and substantial technological advancements in radiopharmaceuticals.

As the healthcare industry pivots toward personalized and targeted treatment modalities, the demand for precise diagnostic tools and effective radiotherapeutics is surging. This places the producers of medicinal radiocompounds at the forefront of a medical revolution. In this blog, we profile the Top 10 Companies in the Medicinal Radiocompounds Industry—a group of pharmaceutical giants, specialized manufacturers, and imaging innovators who are defining the future of nuclear medicine.

Download FREE Sample Report:
Medicinal Radiocompounds Market – View in Detailed Research Report

---

🔟 1. Curium Pharma

Headquarters: Saint-Louis, France
Key Offering: Diagnostic & Therapeutic Radiopharmaceuticals (e.g., FDG, Lutathera, Illuccix)

Curium is a world leader in nuclear medicine, dedicated to the development, manufacturing, and commercialization of diagnostic and therapeutic radiopharmaceuticals. Formed from the fusion of Mallinckrodt Nuclear Medicine and IBA Molecular, Curium has a vast portfolio that supports oncology, cardiology, and neurology applications.

Key Innovations:

• Leading supplier of Fluorodeoxyglucose (FDG) for PET imaging

• Commercialization of Prostate-Specific Membrane Antigen (PSMA) targeted agents like Illuccix

• Production of Lutathera® for neuroendocrine tumors

---

9️⃣ 2. Lantheus Holdings, Inc.

Headquarters: North Billerica, Massachusetts, USA
Key Offering: Defininity®, PYLARIFY®, TechneLite®

Lantheus is a pioneering company with a comprehensive portfolio of diagnostic and therapeutic radiopharmaceuticals. The company is renowned for its cardiovascular imaging agents and its groundbreaking product, PYLARIFY®, a PSMA PET imaging agent for prostate cancer.

Key Innovations:

• PYLARIFY® is one of the fastest-growing PET imaging agents in oncology

• Strong focus on precision diagnostics and theranostics

• Robust manufacturing and supply chain for short-lived radioisotopes

---

8️⃣ 3. Novartis AG

Headquarters: Basel, Switzerland
Key Offering: Lutathera®, Pluvicto™

Novartis has established itself as a dominant force in the therapeutic radiopharmaceutical space through its Advanced Accelerator Applications (AAA) acquisition. The company is at the forefront of the theranostics revolution, pairing diagnostics with targeted radioligand therapies.

Key Innovations:

• Pluvicto™ (177Lu-PSMA-617) for metastatic castration-resistant prostate cancer

• Global infrastructure for the complex logistics of radioligand therapy

• Significant investment in R&D for next-generation radiocompounds

---

7️⃣ 4. Cardinal Health, Inc.

Headquarters: Dublin, Ohio, USA
Key Offering: Nuclear Pharmacy Services, Technetium Generators

Cardinal Health operates one of the largest networks of nuclear pharmacies in North America. The company is critical to the radiopharmaceutical supply chain, providing essential isotopes and compounded doses to hospitals and imaging centers daily.

Key Innovations:

• Extensive network ensuring reliable delivery of time-sensitive radiopharmaceuticals

• Leading supplier of Technetium-99m generators (TechneLite®)

• Specialized logistics for cold-chain and radiation safety compliance

Download FREE Sample Report:
Medicinal Radiocompounds Market – View in Detailed Research Report

---

6️⃣ 5. GE Healthcare

Headquarters: Chicago, Illinois, USA
Key Offering: Contrast Agents, Imaging Equipment, Radiopharmaceuticals

GE Healthcare is a titan in the medical imaging industry, providing not only the diagnostic equipment (PET/CT, SPECT scanners) but also the radiopharmaceuticals that make them work. Their integrated approach positions them uniquely in the market.

Key Innovations:

• Production of key radioisotopes like Fluorine-18 and generators for Technetium-99m

• Development of novel PET tracers for neurology and oncology

• Combining imaging agents with AI-powered analytics software

---

5️⃣ 6. Bracco Imaging S.p.A.

Headquarters: Milan, Italy
Key Offering: Diagnostic Imaging Agents, Contrast Media, Radiopharmaceuticals

Bracco Imaging is a global leader in diagnostic imaging, with a strong and growing presence in nuclear medicine. The company invests heavily in research to develop new molecules for enhanced disease detection and characterization.

Key Innovations:

• Broad portfolio of contrast agents used in conjunction with radiocompounds

• Strategic focus on molecular imaging and theranostics

• Partnerships with research institutions for tracer development

---

4️⃣ 7. Bayer AG

Headquarters: Leverkusen, Germany
Key Offering: Contrast Media, Radiopharmaceuticals (incl. recently acquired products)

Bayer’s radiology division is a major player, particularly in contrast media. The company is expanding its nuclear medicine footprint through acquisitions and internal R&D, aiming to provide comprehensive solutions from diagnosis to treatment monitoring.

Key Innovations:

• Strong legacy in X-ray and MRI contrast agents, synergizing with nuclear medicine

• Investment in targeted alpha therapy (TAT) research

• Digital health platforms integrating imaging data

---

3️⃣ 8. China Isotope & Radiation Corporation (CIRC)

Headquarters: Beijing, China
Key Offering: Radioisotopes, Radiopharmaceuticals, Irradiation Services

As a key state-owned enterprise, CIRC dominates the nuclear technology market in China. It is instrumental in the production and supply of stable and radioactive isotopes, catering to the rapidly growing domestic demand for medicinal radiocompounds.

Key Innovations:

• Large-scale production of Molybdenum-99/Tc-99m generators for the Asian market

• Government-backed initiatives to achieve self-sufficiency in radioisotope supply

• Expansion into therapeutic radiopharmaceuticals

---

2️⃣ 9. Jubilant Pharma Limited

Headquarters: Noida, India
Key Offering: Radiopharmaceuticals, Radioisotopes, Contract Manufacturing

Jubilant Pharma is a significant global player, especially in generics and proprietary radiopharmaceuticals. Its Radiopharmaceuticals division has a strong presence in North America and is expanding globally, focusing on both diagnostics and therapeutics.

Key Innovations:

• Diverse product portfolio including Cardiolite® and Technetium-based agents

• Vertically integrated operations from isotope production to pharmacy distribution

• Strategic partnerships for the development of novel radiocompounds

---

1️⃣ 10. Eli Lilly and Company (through acquisition of Point Biopharma)

Headquarters: Indianapolis, Indiana, USA
Key Offering: Oncology Therapeutics, Radiopharmaceuticals (Emerging)

Eli Lilly’s major acquisition of Point Biopharma in 2023 signaled a powerful entry into the radiopharmaceutical arena. This move positions Lilly to become a leader in next-generation radioligand therapies for cancer.

Key Innovations:

• Gaining access to Point Biopharma’s pipeline of targeted radioligand therapies

• Leveraging Lilly’s global oncology commercial infrastructure

• Significant R&D investment to accelerate the development of precision oncology treatments

Get Full Report Here:
Medicinal Radiocompounds Market – View in Detailed Research Report

---

🔬 Outlook: The Future of Medicinal Radiocompounds Is Targeted and Therapeutic

The medicinal radiocompounds market is experiencing a paradigm shift from purely diagnostic agents to integrated theranostic platforms. The convergence of diagnostics and therapy is creating unprecedented opportunities for personalized medicine, particularly in oncology.

📈 Key Trends Shaping the Market:

• Theranostics Boom: The pairing of diagnostic radiocompounds with their therapeutic counterparts is revolutionizing cancer care, enabling treatment based on specific biomarkers.

• Novel Radioisotopes: Research into alpha-emitting isotopes (e.g., Actinium-225) and other novel radionuclides promises more potent and precise therapies with fewer side effects.

• Supply Chain Resilience: Global efforts are underway to diversify the production of key isotopes like Molybdenum-99 to prevent shortages and ensure stable supply.

• Regulatory Support: Expedited pathways from regulatory bodies like the FDA are accelerating the approval of promising radiopharmaceuticals, bringing them to patients faster.

Get Full Report Here:
Medicinal Radiocompounds Market – View in Detailed Research Report

The companies profiled above are not just supplying critical medical products—they are actively building the foundation for the next era of precision medicine, where diagnosis and treatment are seamlessly linked for better patient outcomes.